The main objective of this study is to compare the distribution of Florbetaben (NEURACEQ: FBB) in the brain in amyloid cerebral angiopathy (ACA) manifested by isolated hemosiderosis in non-demented patients with that observed in healthy subjects, patients with ACA and with lobar hematoma(s) and patients with Alzheimer's dementia without MRI signs in favor of ACA.

Start Date01 Jul 2020

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nimes

100 Clinical Results associated with Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

100 Translational Medicine associated with Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

100 Patents (Medical) associated with Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

1,447

Literatures (Medical) associated with Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

02 Dec 2024·Journal of Biomolecular Structure and Dynamics

Antitumor activities of a novel fluorinated small molecule (A1) in CT26 colorectal cancer cells: molecular docking and in vitro studies

Article

Author: Hassanshahi, Gholamhossein ; Falak, Reza ; Khoshmirsafa, Majid ; Bagherzadeh, Kowsar ; Rahimi, Ali ; Safari, Elaheh ; Karimi, Milad ; Khorramdelazad, Hossein ; Mohammadi, Mahdi ; Darehkordi, Ali

Chemotherapeutic treatment of colorectal cancer (CRC) has not been satisfactory until now; therefore, the discovery of more efficient medications is of great significance. Based on available knowledge, the CXCL12/CXCR4 axis plays a significant role in tumorigenesis, and inhibition of CXCR4 chemokine receptor with AMD3100 is one of the most known therapeutic modalities in cancer therapy. Herein, N, N''-thiocarbonylbis(N'-(3,4-dimethylphenyl)-2,2,2-trifluoroacetimidamide) (A1) was synthesized as a potent CXCR4 inhibitor. A1 inhibitory activity was first evaluated employing Molecular Docking simulations in comparison with the most potent CXCR4 inhibitors. Then, the antiproliferative and cytotoxic effect of A1 on CT26 mouse CRC cells was investigated by MTT assay technique and compared with those of the control molecule, AMD3100. The impact of the target compounds IC₅₀ on apoptosis, cell cycle arrest, and CXCR4 expression was determined by flow cytometry technique. Our finding demonstrated that A1 induces a cytotoxic effect on CT26 cells at 60 μg/mL concentration within 72 h and provokes cell apoptosis and G2/M cell cycle arrest in comparison with the untreated cells, while AMD3100 did not show a cytotoxic effect up to 800 μg/mL dose. The obtained results show that A1 (at a concentration of 40 μg/mL) significantly reduced the proliferation of CT26 cells treated with 100 ng/mL of CXCL12 in 72 h. Moreover, treatment with 60 μg/mL of A1 and 100 ng/mL of CXCL12 for 72 h significantly decreased the number of cells expressing the CXCR4 receptor compared to the control group treated with CXCL12. Eventually, the obtained results indicate that A1, as a dual-function fluorinated small molecule, may benefit CRC treatment through inhibition of CXCR4 and exert a cytotoxic effect on tumor cells.Communicated by Ramaswamy H. Sarma.

01 Nov 2024·Protoplasma

Chemically induced phenotype plasticity in the unicellular zygnematophyte, Penium margaritaceum

Article

Author: Tomasi, Tawn ; Sgambettera, Gabriel ; Domozych, David S ; Lu, Iris ; Bagdan, Kaylee ; LoRicco, Josephine G ; Malone, Stuart

AbstractPhenotypic plasticity allows a plant cell to alter its structure and function in response to external pressure. This adaptive phenomenon has also been important in the evolution of plants including the emergence of land plants from a streptophyte alga. Penium margaritaceum is a unicellular zygnematophyte (i.e., the group of streptophyte algae that is sister to land plants) that was employed in order to study phenotypic plasticity with a focus on the role of subcellular expansion centers and the cell wall in this process. Live cell fluorescence labeling, immunofluorescence labeling, transmission electron microscopy, and scanning electron microscopy showed significant subcellular changes and alterations to the cell wall. When treated with the actin-perturbing agent, cytochalasin E, cytokinesis is arrested and cells are transformed into pseudo-filaments made of up to eight or more cellular units. When treated with the cyclin-dependent kinase (CDK) inhibitor, roscovitine, cells converted to a unique phenotype with a narrow isthmus zone.

01 Sep 2024·Free Radical Research

Reduction of oxidative damage in prostate tissue caused by radiation and/or chloroquine by apocynin

Article

Author: Ertik, Onur ; Us, Huseyin ; Sezen Us, Ayca ; Coremen, Melis ; Yanardag, Refiye ; Karabulut Bulan, Omur ; Gul, Ilknur Bugan

Prostate damage can occur in men due to age and genetic factors, especially when exposed to external factors. Radiation (RAD) is a prominent factor leading to oxidative stress and potential prostate damage. Additionally, chloroquine (CQ), used in malaria treatment, can induce oxidative stress in a dose-dependent manner. Therefore, reducing and preventing oxidative damage in prostate tissue caused by external factors is crucial. Rats used in the study were divided into seven groups, CQ, apocynin (APO), RAD, CQ + APO, CQ + RAD, APO + RAD, CQ + APO + RAD. Subsequently, in vivo biochemical parameters of prostate tissues were examined, including reduced glutathione, lipid peroxidation, superoxide dismutase, glutathione reductase, glutathione peroxidase, glutathione-S-transferase activities, and total antioxidant status, total oxidant status, reactive oxygen species, oxidative stress index, advanced oxidation protein products and histologically. The in vivo results presented in our study showed that APO reduced oxidative stress and had a protective effect on prostate tissue in the CQ, RAD, and CQ + RAD groups as a results of biochemical and histological experiments. Additionally, in silico studies revealed a higher binding affinity of diapocynin to target proteins compared to APO. As a histological results, RAD and CQ alone or in combination did not induce damage in prostate tissues, whereas mild histopathological findings such as hyperemia and haemorrhage were observed in all APO-treated groups. The results suggest that the use of APO for the treatment of oxidative damage induced by CQ and RAD in rats.

100 Deals associated with Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperlipidemias	Phase 2	US	-	-
Kaposi Sarcoma	Phase 2	US	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAIC2019	Not Applicable	Dementia	-	APOLIPOPROTEIN E (ApoE in HDL that lacks apoC3)	bdccrcccph(tnlfgtnkjc): P-Value = 0.67 View more	-	01 Jul 2019
				APOLIPOPROTEIN E (ApoE in HDL that contains apoC3)
AAIC2016	Not Applicable	Dementia	809	Apolipoprotein E (homozygous E4 carriers)	aoeoubwumz(dwtzjmfadj) = subvahmcrv rsukssgady (mdqgzmlwob )	-	01 Jul 2016
				Apolipoprotein E (heterozygous E4 carriers)	aoeoubwumz(dwtzjmfadj) = tmjofqnajy rsukssgady (mdqgzmlwob )
EULAR2016	Not Applicable	Apo E	-	APOLIPOPROTEIN E	pfwijyixuh(sfujiwskcd) = louriiqevu lrvvzjsgmh (frzvcmeytq ) View more	-	08 Jun 2016
EULAR2010	Not Applicable	Fractures, Bone Apolipoprotein E	-	APOLIPOPROTEIN E	(qdcofalzif) = ttnpgaijvv gtlhdmnsri (ygtdzocrvq ) View more	-	16 Jun 2010

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation